Physician profile
Robert Strehlow
NPI 1467893404
$7,096.88
in general payments reported to CMS, 2019-2025
46 companies · $699 in 2025
The $699 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $1,026 · 2021: $1,724 · 2022: $1,082 · 2023: $1,134 · 2024: $942 · 2025: $699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,729 · Travel and Lodging: $45.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,728.84 |
| Travel and Lodging | $45.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $1,525.12 | 2020-2025 | Speedicath, Altis |
| Astellas Pharma US INC | $967.94 | 2019-2025 | Myrbetriq, Xtandi |
| Procept Biorobotics Corporation | $579.10 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Abbvie INC. | $533.80 | 2019-2025 | Botox |
| Janssen Biotech, INC. | $465.87 | 2019-2025 | Erleada |
| Antares Pharma, INC. | $396.27 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Biotissue Holdings INC. | $261.90 | 2023 | |
| Merck Sharp & Dohme LLC | $209.14 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Tolmar Pharmaceuticals, INC. | $169.37 | 2019-2021 | |
| Pfizer INC. | $165.46 | 2019-2023 | |
| Boston Scientific Corporation | $163.26 | 2019-2025 | Ams 700, Watchman Flx, Xpeeda Dsl Fiber |
| Urogen Pharma, INC. | $140.98 | 2022-2025 | Jelmyto |
| Pacira Pharmaceuticals Incorporated | $133.41 | 2021 | |
| Clarus Therapeutics INC. | $92.93 | 2021 | |
| Smith+Nephew, INC. | $83.09 | 2020-2023 | Stravix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Strehlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.